Weiss Ratings Reiterates “Sell (E+)” Rating for 111 (NASDAQ:YI)

Weiss Ratings reiterated their sell (e+) rating on shares of 111 (NASDAQ:YI) in a research report report published on Wednesday morning,Weiss Ratings reports.

111 Price Performance

NASDAQ:YI opened at $8.36 on Wednesday. The business’s 50-day moving average is $6.40 and its two-hundred day moving average is $7.40. The firm has a market capitalization of $71.48 million, a PE ratio of -2.09 and a beta of 0.41. 111 has a 12 month low of $4.14 and a 12 month high of $15.80.

111 (NASDAQ:YI) last posted its earnings results on Wednesday, November 27th. The company reported ($0.20) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On 111

Institutional investors have recently added to or reduced their stakes in the company. FIL Ltd purchased a new stake in 111 during the 4th quarter worth approximately $450,000. Napean Trading & Investment Co Singapore PTE Ltd purchased a new position in shares of 111 during the 4th quarter valued at approximately $245,000. Finally, JPMorgan Chase & Co. grew its position in shares of 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after buying an additional 305,339 shares in the last quarter. Institutional investors and hedge funds own 21.32% of the company’s stock.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.